Functional genomics lead to new therapies in follicular lymphoma

Annals of the New York Academy of Sciences

Volumn 1293, Issue 1, 2013, Pages 18-24

  Oricchio, Elisa ^a   Wendel, Hans Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Genomic data; Mouse model; Therapies

Indexed keywords

EPHRIN RECEPTOR A7;

ARTICLE; CANCER GENETICS; CANCER THERAPY; CHROMOSOME 6Q; FOLLICULAR LYMPHOMA; FUNCTIONAL GENOMICS; GENE MUTATION; HUMAN; NONHUMAN; TUMOR SUPPRESSOR GENE;

MURINAE;

EID: 84880930644     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12120     Document Type: Article

References (70)

1. Oricchio, E. et al. 2011. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147: 554-564.
2. Beroukhim, R. et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
3. Segal, E., N. Friedman, D. Koller & A. Regev. 2004. A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36: 1090-1098.
4. Fudenberg, G., G. Getz, M. Meyerson & L.A. Mirny. 2011. High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat. Biotechnol. 29: 1109-1113.
5. Hanahan, D. & R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
6. Welch, J.S. et al. 2012. The origin and evolution of mutations in acute myeloid leukemia. Cell 150: 264-278.
7. Bric, A. et al. 2009. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16: 324-335.
8. Ngo, V.N. et al. 2006. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441: 106-110.
9. Mavrakis, K.J. et al. 2010. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat. Cell Biol. 12: 372-379.
10. Zuber, J. et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.
11. Zender, L. et al. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864.
12. Egle, A., A.W. Harris, M.L. Bath, et al. 2004. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103: 2276-2283.
13. Wendel, H.G. et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
14. Schatz, J.H. et al. 2011. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J. Exp. Med. 208: 1799-1807.
15. Harris, A.W. et al. 1988. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167: 353-371.
16. Cattoretti, G. et al. 2005. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7: 445-455.
17. Gladden, A.B., R. Woolery, P. Aggarwal, et al. 2006. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25: 998-1007.
18. Tsujimoto, Y., J. Cossman, E. Jaffe & C.M. Croce. 1985. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443.
19. Kridel, R., L.H. Sehn & R.D. Gascoyne. 2012. Pathogenesis of follicular lymphoma. J. Clin. Invest. 122: 3424-3431.
20. Dave, S.S. et al. 2004. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159-2169.
21. Martinez-Climent, J.A. et al. 2003. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101: 3109-3117.
22. Lo Coco, F. et al. 1993. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82: 2289-2295.
23. Nanjangud, G. et al. 2007. Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenet. Genome Res. 118: 337-344.
24. Cheung, K.J. et al. 2009. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 113: 137-148.
25. Colombat, P. et al. 2001. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101-106.
26. Maloney, D.G. 2012. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 366: 2008-2016.
27. Solal-Celigny, P. 2006. Follicular lymphoma international prognostic index. Curr. Treat. Options Oncol. 7: 270-275.
28. Federico, M. et al. 2009. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J. Clin. Oncol. 27: 4555-4562.
29. Morin, R.D. et al. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
30. Yap, D.B. et al. 2011. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451-2459.
31. Challa-Malladi, M. et al. 2011. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20: 728-740.
32. Davis, R.E. et al. 2010. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92.
33. Yunis, J.J. et al. 1987.Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer. N. Engl. J. Med. 316: 79-84.
34. Compagno, M. et al. 2009. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717-721.
35. Kato, M. et al. 2009. Frequent inactivation of A20 in B-cell lymphomas. Nature 459: 712-716.
36. Mandelbaum, J. et al. 2010. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18: 568-579.
37. Dawson, D.W. et al. 2007. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26: 4243-4252.
38. Pasquale, E.B. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10: 165-180.
39. Pasquale, E.B. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52.
40. Depaepe, V. et al. 2005. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435: 1244-1250.
41. Rashid, T. et al. 2005. Opposing gradients of ephrin-As and EphA7 in the superior colliculus are essential for topographic mapping in the mammalian visual system. Neuron 47: 57-69.
42. Holmberg, J., D.L. Clarke & J. Frisen. 2000. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408: 203-206.
43. Weinstein, I.B. 2002. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
44. Ventura, A. et al. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665.
45. Luo, J., N.L. Solimini & S.J. Elledge. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
46. Wang, J. et al. 2005. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24: 5637-5647.
47. Kuang, S.Q. et al. 2010. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115: 2412-2419.
48. Guan, M., C. Xu, F. Zhang & C. Ye. 2009. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer 124: 88-94.
49. Barretina, J. et al. 2010. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42: 715-721.
50. Peifer, M. et al. 2012. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44: 1104-1110.
51. Stransky, N. et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
52. Hodis, E. et al. 2012. A landscape of driver mutations in melanoma. Cell 150: 251-263.
53. Imielinski, M. et al. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120.
54. Grasso, C.S. et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
55. Rudin, C.M. et al. 2012. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44: 1111-1116.
56. Druker, B.J. et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
57. Poulikakos, P.I., C. Zhang, G. Bollag, et al. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
58. Druker, B.J. et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355: 2408-2417.
59. Al-Lazikani, B., U. Banerji & P. Workman. 2012. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30: 679-692.
60. Scuoppo, C. et al. 2012. A tumour suppressor network relying on the polyamine-hypusine axis. Nature 487: 244-248.
61. Solimini, N.L. et al. 2012. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 337: 104-109.
62. Nijhawan, D. et al. 2012. Cancer vulnerabilities unveiled by genomic loss. Cell 150: 842-854.
63. Ding, L., G. Getz, D.A. Wheeler, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
64. Seshagiri, S., E.W. Stawiski, S. Durinck, et al. 2012. Recurrent R-spondin fusions in colon cancer. Nature 488: 660-664.
65. Robinson, G., M. Parker, T.A. Kranenburg, et al. 2012. Novel mutations target distinct subgroups of medulloblastoma. Nature 488: 43-48.
66. Stephens, P.J., P.S. Tarpey, H. Davies, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
67. Guo, G., Y. Gui, S. Gao, et al. 2011. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44: 17-19.
68. Banerji, S., K. Cibulskis, C. Rangel-Escareno, et al. 2012. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409.
69. Barbieri, C.E., S.C. Baca, M.S. Lawrence, et al. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44: 685-689.
70. Jones, D.T., N. Jäger, M. Kool, et al. 2012. Dissecting the genomic complexity underlying medulloblastoma. Nature 488: 100-105.